Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Pfizer's Innovative Drug Pipeline Provides Ample Reason To Buy It Here
03:30pm, Friday, 12'th Apr 2024
Pfizer has faced numerous challenges, including a decline in COVID-19 vaccine demand and high costs, but the worst is likely priced into the stock. The company is focusing on innovation and has ambiti
Is Pfizer Stock the Biggest Bargain in the S&P 500?
05:50am, Friday, 12'th Apr 2024
Pfizer's PEG ratio according to one widely used financial website is shockingly low. This low valuation metric raises questions.
Pfizer: The Market Is Wrong
03:00pm, Thursday, 11'th Apr 2024
Over the last twelve months, Pfizer's stock experienced a massive sell-off due to a massive revenue and EPS drop after the COVID-related spikes of 2021 and 2022. However, the company's financial perfo
Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
10:16am, Thursday, 11'th Apr 2024
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
7 Healthcare Stocks to Keep Your Portfolio in Tip-Top Shape
01:22pm, Wednesday, 10'th Apr 2024
With rising concerns in the market potentially forcing a strategic shift, investors may want to consider healthcare stocks. No matter what happens, people need access to health-related products and se
Pfizer's (PFE) RSV Vaccine Study in Adults Under 60 Meets Goal
10:31am, Wednesday, 10'th Apr 2024
Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.
Where Will Pfizer Stock Be in 10 Years?
02:06am, Wednesday, 10'th Apr 2024
Drug giant Pfizer has been investing big money into oncology in recent years. In a decade, the company's product mix may look significantly different than today.
RSV Vaccine Could Protect High-Risk Adults Under 60, Pfizer Says
10:47am, Tuesday, 09'th Apr 2024
A late-stage trial of Pfizer's RSV vaccine showed promising results in adults under 60 years old, suggesting the shot could help people as young as 18, the company announced Tuesday, amid an effort to
Pfizer Stock Rises on Upbeat RSV Vaccine Trial Data
10:25am, Tuesday, 09'th Apr 2024
Pfizer Inc (NYSE PFE) stock is up 1.7% at $27.04 at last check, following news a late-stage trial of its respiratory syncytial virus (RSV) vaccine Abrysvo generated an immune response in higher r
Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
06:45am, Tuesday, 09'th Apr 2024
Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers.
3 Dirt-Cheap Stocks That Could Make You Filthy Rich
06:15am, Tuesday, 09'th Apr 2024
The stock market's been wobbly in the past couple of weeks, influenced by Federal Reserve officials' cautious stance on cutting interest rates. However, with a cooling job market, it's only a matter o
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
05:50am, Tuesday, 09'th Apr 2024
Ken Griffin's Citadel hedge fund more than quadrupled its stake in this stock in 2023 Q4. Griffin probably likes the stock because of its valuation, dividend, and surprisingly robust growth prospects.
Pfizer (PFE) Declines More Than Market: Some Information for Investors
06:51pm, Monday, 08'th Apr 2024
In the latest trading session, Pfizer (PFE) closed at $26.58, marking a -0.3% move from the previous day.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
10:06am, Monday, 08'th Apr 2024
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
This S&P 500 Dividend Stock Could Be the Best Bad-News Buy on the Market
05:47am, Monday, 08'th Apr 2024
Pfizer has had plenty of bad news, with more on the way. New products and acquisitions should help the drugmaker return to growth.
